Atrial natriuretic factor as marker of myocardial compromise in Chagas' disease

Puyó, Ana María; Scaglione, Jorge; Auger, Sergio; Cavallero, Susana; Donoso, Alfredo O.; Dupuy, Horacio A; Fernández, Belisario E.

doi:10.1016/s0167-0115(02)00016-2

Cited by 14 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surprisingly, although CD affects almost 18 million people in Latin America, apart from our group only three publications [17, 18] reported ANP [19] or BNP [20, 21] regulation in human CD patients.…”

Section: Discussionmentioning

confidence: 65%

See 1 more Smart Citation

Prognostic Value of Natriuretic Peptides in Chagas’ Disease: A 3-Year Follow-Up Investigation

Moreira

Heringer-Walther²,

Wessel³

et al. 2007

Cardiology

View full text Add to dashboard Cite

Background: Chagas’ disease (CD) affects around 18 million people in Latin America. To determine the diagnostic and prognostic value of natriuretic peptides in patients with CD, we measured atrial (ANP) and brain natriuretic peptide (BNP), and compared the findings with other dilated cardiomyopathies (DCM). Methods: Blood samples were obtained from 111 CD patients, 62 patients with DCM due to other causes, and 43 gender- and age-matched healthy subjects. The CD and DCM patients were subdivided according to their NYHA classification. Natriuretic peptide concentrations were determined by immunoradiometric assays. Results: ANP and more pronounced BNP levels were increased in CD and DCM patients in relation to the NYHA class. Circulating BNP concentrations were higher in CD patients in NYHA classes I–II than in the corresponding DCM patients (p = 0.020). Importantly, ANP and BNP were already significantly elevated in CD patients without systolic ventricular dysfunction (p ≤ 0.001). In CD patients, both peptides were highly correlated with echocardiographic parameters (p < 10^–14). Both ANP and BNP had comparable ability to predict death or the necessity for heart transplant (p < 0.0001). Conclusion: Natriuretic peptide levels can be used as a marker of asymptomatic CD without ventricular dysfunction and thus could be an ideal tool to identify these patients for early therapy.

show abstract

Section: Discussionmentioning

confidence: 65%

“…Other authors found that ANP was elevated in the acute/chronic phase of T. cruzi infection in rats [22], and it has been shown that ANP levels cannot differentiate between CD and non-CD patients who have conduction defects or CHF [19]. However, our study is the first to investigate both natriuretic peptides in the plasma of CD patients.…”

Section: Discussionmentioning

confidence: 71%

Prognostic Value of Natriuretic Peptides in Chagas’ Disease: A 3-Year Follow-Up Investigation

Moreira

Heringer-Walther²,

Wessel³

et al. 2007

Cardiology

View full text Add to dashboard Cite

show abstract

“…Plasma NP extraction and ANP RIA were performed as described by Sarda et al (20). Anti-human ANP-(99 -126) was purchased from Peninsula Laboratories (Belmont, CA) and 125 I-labeled ANP from New England Biolabs (Boston, MA) (15). Plasma BNP was measured in extracts using a BNP-45 RIA commercial kit (Phoenix Pharmaceuticals, Burlingame, CA).…”

Section: Methodsmentioning

confidence: 99%

Ventricular function and natriuretic peptides in sequentially combined models of hypertension

Cavallero

Gónzalez²,

Seropián³

et al. 2010

American Journal of Physiology-Heart and Circulatory Physiology

Self Cite

View full text Add to dashboard Cite

Hemodynamic parameters and natriuretic peptide levels were evaluated in cardiac hypertrophy produced by sequentially applied renovascular (RV) and deoxycorticosterone acetate-salt (DS) models of hypertension. We studied hypertensive rats by RV or DS treatment at 2 and 4 wk, as well as by the combination of 2 wk of each treatment in an inverse sequence: RV 2 wk/DS 2 wk (RV2/DS2) and DS 2 wk/RV 2 wk (DS2/RV2). The in vivo cardiac function, interstitial fibrosis, and synthesis and secretion of types A (ANP) and B (BNP) natriuretic peptides were monitored in hypertensive models compared with their corresponding sham (Sh2, Sh4). There were no differences in relaxation parameters among RV or DS groups and combined treatments. Left ventricular +dP/dt(max) increased only in RV4 (P < 0.01 vs. Sh4), and this increase was abolished in RV2/DS2. Interstitial collagen concentration increased after 4 wk in both RV4 and RV2/DS2 groups. Although there were no changes in collagen concentration in either DS2 or DS4 groups, clipping after 2 wk of DS (DS2/RV2) remarkably stimulated interstitial fibrosis (P < 0.01 vs. DS2). Plasma BNP increased in RV treatment at 4 wk (P < 0.001 vs. Sh4), but not in DS. Interestingly, RV applied after the 2 wk of DS treatment induced a marked increase in BNP levels (P < 0.001 vs. Sh4). In this regard, plasma BNP appears to be a reliable indicator of pressure overload. Our results suggest that the second stimulus of mechanical overload in combined models of hypertension determines the evolution of hypertrophy and synthesis and secretion of ANP and BNP.

show abstract

“…Antihuman ANP (99-126) was purchased from Peninsula Lab. Inc. (Belmont, California, USA) and labelled [ 125 I]ANP from New England Biolabs (Boston, Massachusetts, USA) [19].…”

Section: Anp Radioimmunoassaymentioning

confidence: 99%

Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volume-induced cardiac hypertrophy

Cavallero

Gónzalez²,

Puyó³

et al. 2007

Journal of Hypertension

Self Cite

View full text Add to dashboard Cite

show abstract

Atrial natriuretic factor as marker of myocardial compromise in Chagas' disease

Cited by 14 publications

References 22 publications

Prognostic Value of Natriuretic Peptides in Chagas’ Disease: A 3-Year Follow-Up Investigation

Prognostic Value of Natriuretic Peptides in Chagas’ Disease: A 3-Year Follow-Up Investigation

Ventricular function and natriuretic peptides in sequentially combined models of hypertension

Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volume-induced cardiac hypertrophy

Contact Info

Product

Resources

About